- Patients
- Clinical Research
- Clinical trials
- FURMO-002
2024-02-13T00:00:00.000+11:00
Ongoing
FURMO-002
FURMO-002
Lung cancer
A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumour activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.
A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumour activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Lung cancer
Study Phase
1b
Trial registration
Number: NCT05364073
GenesisCare Location(s)
GenesisCare North Shore
GenesisCare North Shore
:::
Principal Investigator(s)